Novel 11-oxoprostaglandin derivatives
    1.
    发明授权
    Novel 11-oxoprostaglandin derivatives 失效
    新型11-氧代前列腺素衍生物

    公开(公告)号:US4346228A

    公开(公告)日:1982-08-24

    申请号:US677420

    申请日:1976-04-15

    摘要: 11-Oxoprostaglandin derivatives of the formula ##STR1## wherein R.sub.2 is a hydrogen atom or alkyl of 1-5 carbon atoms,R.sub.3 is alkyl of 1-5 carbon atoms, alkylaryl, cycloalkyl of 5-6 ring carbon atoms and a total of 5-10 carbon atoms; benzodioxol-2-yl, phenyl, naphthyl or phenyl or naphthyl substituted by phenyl, halogen, alkyl of 1-4 carbon atoms, chloromethyl, fluoromethyl, carboxyl or hydroxy;A is --CH.sub.2 --CH.sub.2 --, cis--CH.dbd.CH--, or trans--CH.dbd.CH--;B is --CH.sub.2 --CH.sub.2 -- or trans--CH.dbd.CH--,D and E collectively are a direct bond or D is alkylene of 1-5 carbon atoms and E is an oxygen or sulfur atom; esters thereof; readily cleavable 9,15 and 9,15 ethers thereof; methanesulfonylamides thereof, and physiologically acceptable salts thereof with bases; possess the activity of the corresponding natural prostaglandins with a surprisingly longer duration of effectiveness, greater selectivity, and better effects, and can be produced, e.g., by oxidation of the corresponding 9-hydroxy prostaglandins.

    摘要翻译: 其中R2是氢原子或1-5个碳原子的烷基,R3是1-5个碳原子的烷基,烷基芳基,5-6个环碳原子的环烷基和总共5个碳原子的11-前列酰乳糖衍生物 -10个碳原子; 苯基二氧杂环戊烯-2-基,苯基,萘基或被苯基,卤素,1-4个碳原子的烷基取代的苯基或萘基,氯甲基,氟甲基,羧基或羟基; A是-CH 2 -CH 2 - ,顺式-CH = CH-或反式-CH = CH-; B是-CH 2 -CH 2 - 或反式-CH = CH-,D和E共同是直接键或D是1-5个碳原子的亚烷基,E是氧或硫原子; 其酯; 易于切割的9,15和9,15醚; 甲磺酰胺及其与碱的生理学上可接受的盐; 具有相当的天然前列腺素的活性,具有惊人的更长的有效期,更高的选择性和更好的效果,并且可以例如通过相应的9-羟基前列腺素的氧化来产生。

    Novel acetylenic prostaglandin analogs
    2.
    发明授权
    Novel acetylenic prostaglandin analogs 失效
    新型炔类前列腺素类似物

    公开(公告)号:US4073934A

    公开(公告)日:1978-02-14

    申请号:US677861

    申请日:1976-04-16

    CPC分类号: C07D307/935 C07C405/00

    摘要: Optically active and racemic prostaglandin derivatives of the formula ##STR1## wherein R.sub.1 is --OR.sub.5 ; --NHSO.sub.2 CH.sub.3 ; or --O--CH.sub.2 --U--V; R.sub.5 is hydrogen, alkyl, aryl, or a heterocyclic group; U is a direct bond, carbonyl or carbonyloxy; and V is phenyl substituted by 1-3 phenyl, alkoxy of 1-2 carbon atoms, or halogen, preferably bromine;R.sub.2 is hydrogen or alkyl of 1-5 carbon atoms;R.sub.3 is alkyl, substituted or unsubstituted cycloalkyl, straight-chain or branched alkyl of 1-5 carbon atoms substituted by aryl or substituted aryl, when R.sub.1 is as above; or R.sub.3 is aryl or substituted aryl group when R.sub.1 is --OR.sub.5 ', --NHSO.sub.2 CH.sub.3, or --O--CH.sub.2 --U--V and R.sub.5 ' is aryl or a heterocyclic group and U and V are as above;R.sub.4 is hydrogen or an ether or acyl residue;A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--;B is --CH.sub.2 --CH.sub.2 -- or trans--CH.dbd.CH--;D is a direct bond, oxygen, or sulfur;Z is carbonyl or >CH OR.sub.4 wherein OR.sub.4 is in the .alpha.- or .beta.-position; andX y is ##STR2## when Z is >CH OR.sub.4 --, or ##STR3## or --CH.dbd.CH-- when Z is carbonyl; AND, WHEN R.sub.1 is hydroxy, the physiologically compatible salts thereof with bases, have more prolonged activity than naturally-occurring prostaglandins.

    摘要翻译: 式(Ⅰ)的光学活性和外消旋前列腺素衍生物,其中R1为-OR5; -NHSO 2 CH 3; 或-O-CH 2 -U-V; R5是氢,烷基,芳基或杂环基; U是直接键,羰基或羰氧基; 并且V是被1-3个苯基,1-2个碳原子的烷氧基或卤素,优选溴取代的苯基; R2是氢或1-5个碳原子的烷基; R 3为烷基,取代或未取代的环烷基,被芳基或取代芳基取代的1-5个碳原子的直链或支链烷基,当R 1如上所述时; 或当R 1为-OR 5',-NHSO 2 CH 3或-O-CH 2 -U-V且R 5'为芳基或杂环基时,R 3为芳基或取代的芳基,U和V如上所述; R4是氢或醚或酰基残基; A是-CH 2 -CH 2 - 或顺式-CH = CH-; B是-CH 2 -CH 2 - 或反式-CH = CH-; D是直接键合,氧或硫; Z是羰基或> CH OR 4,其中OR 4在α或β-位; 当Z为羰基时Z为> CH OR4-或或-CH = CH-时,X Y为 当R1是羟基时,其与碱的生理上相容的盐比天然存在的前列腺素具有更长的活性。

    9-fluoroprostaglandin derivatives, their preparation and use as
medicinal agents
    4.
    发明授权
    9-fluoroprostaglandin derivatives, their preparation and use as medicinal agents 失效
    9-氟前列腺素衍生物,其制备和用作药物

    公开(公告)号:US4789685A

    公开(公告)日:1988-12-06

    申请号:US4733

    申请日:1987-01-20

    摘要: 9-fluoroprostane derivatives of Formula I ##STR1## wherein R.sub.1 is CH.sub.2 OH or ##STR2## wherein R.sub.2 is hydrogen, alkyl, cycloalkyl, aryl, or a heterocyclic residue; or R.sub.1 is the residue ##STR3## wherein R.sub.3 is an acid residue or R.sub.2 and A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--,B is --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH-- or --C.tbd.C,W is a free or functionally modified hydroxymethylene group wherein the OH-group can be in the .alpha.- or .beta.- position,D and E jointly are a direct bond orD is straight-chain or branched alkylene or alkenylene of 1-10 carbon atoms which can optionally be substituted by fluorine atoms, and E is oxygen or sulfur, a direct bond, --C.tbd.C-- or --CR.sub.6 .dbd.CR.sub.7 -- wherein R.sub.6 and R.sub.7 differ from each other and each is hydrogen, chlorine, or alkyl,R.sub.4 is a free or functionally modified hydroxy group, andR.sub.5 is hydrogen, an optionally substituted aliphatic group, e.g., alkyl or halosubstituted alkyl, cycloalkyl, optionally substituted aryl or a heterocyclic group, and, when R.sub.2 is H, the physiologically compatible salts thereof with bases,have valuable pharmacological properties, e.g., as luteolytics or abortifacients.

    摘要翻译: 其中R 1是CH 2 OH或其中R 2是氢,烷基,环烷基,芳基或杂环残基的式I的α-氟仿烷基衍生物。 或R1是残基,其中R3是酸残基或R2和A是-CH2-CH2-或顺式-CH = CH-,B是-CH2-CH2-,反式-CH = CH-或-C3BOND C,W是游离的或官能改性的羟基亚甲基,其中OH基可以是α或β位,D和E共同是直接键,或D是1-10的直链或支链亚烷基或亚链烯基 可以任选被氟原子取代的碳原子,E是氧或硫,直接键,-C 3 D或-CR 6 = CR 7 - ,其中R 6和R 7彼此不同,各自是氢,氯或烷基 R4是游离的或官能改性的羟基,R5是氢,任意取代的脂族基团,例如烷基或卤代取代的烷基,环烷基,任选被取代的芳基或杂环基,当R2是H时,生理上相容的盐 具有有价值的药理学性质,例如作为骨质疏松症或流产者。

    9-halogen-(Z)-prostaglandin derivatives, process for their production and their use as pharmaceutical agents
    5.
    发明授权
    9-halogen-(Z)-prostaglandin derivatives, process for their production and their use as pharmaceutical agents 失效
    9-卤素 - (Z) - 前列腺素衍生物,其制备方法及其作为药剂的用途

    公开(公告)号:US06225347B1

    公开(公告)日:2001-05-01

    申请号:US08313667

    申请日:1994-09-27

    IPC分类号: C07C40500

    摘要: The invention relates to 9-halogen-(Z) prostane derivatives of formula I in which Z represents the radicals Hal represents a chlorine or fluorine atom in the alpha or beta position, R1 represents the radical with R2 meaning a hydrogen atom, an alkyl, cycloalkyl, aryl or heterocyclic radical or R1 represents the radical with R3 meaning an acid radical or the radical R2 and A represents a —CH2—CH2—, a trans-CH═CH or —C≡C group, W represents a free or a functionally modified group, and the respective OH groups can be in the alpha or beta position, D and E together represent a direct bond or D represents a straight-chain alkylene group with 1-10 C atoms, a branched-chain alkylene group with 2-10 C atoms or an annular alkylene group with 3-10 C atoms, which optionally can be substituted by fluorine atoms, and E represents an oxygen or sulfur atom, a direct bond, a C≡C bond or a —CR6═CR7 group, and R6 and R7 are different and mean a hydrogen atom, a chlorine atom or a C1-C4 alkyl group, R4 resents a free or functionally modified hydroxy group, R5 means a hydrogen atom, an alkyl, a halogen-substituted alkyl, a cycloalkyl or an optionally substituted aryl or a heterocyclic group, and if R2 means a hydrogen atom, its salts with physiologically compatible bases or its cyclodextrin chlathrates, process for their production and their pharmaceutical use.

    摘要翻译: 本发明涉及式Iin的9-卤素 - (Z)前列腺衍生物,其中Z代表基团.Hal表示α或β位上的氯或氟原子,R 1表示R 2表示氢原子,烷基,环烷基,芳基或 杂环基或R 1表示基团,其中R 3表示酸基或基团R 2且A表示-CH 2 -CH 2 - ,反式-CH = CH或-C = C基团,W表示游离或功能修饰基团, OH基可以是α或β位,D和E一起代表直接键或D表示具有1-10个C原子的直链亚烷基,具有2-10个C原子的支链亚烷基或环状亚烷基 具有3-10个C原子的基团,其任选地可以被氟原子取代,E表示氧或硫原子,直接键合,C = C键或-CR 6 = CR 7基团,并且R 6和R 7不同, 一个氢原子,一个氯原子或一个C 1 -C 4烷基,R 4是一个游离的 或官能改性的羟基,R 5表示氢原子,烷基,卤素取代的烷基,环烷基或任选取代的芳基或杂环基,如果R 2表示氢原子,则其与生理上相容的碱或其环糊精的盐 chlathrates,生产过程及其药物用途。

    9-halogen-(Z) prostaglandin derivatives, process for their production
and their use as pharmaceutical agents
    6.
    发明授权
    9-halogen-(Z) prostaglandin derivatives, process for their production and their use as pharmaceutical agents 失效
    9-卤素 - (Z)前列腺素衍生物,其制备方法及其作为药剂的用途

    公开(公告)号:US5891910A

    公开(公告)日:1999-04-06

    申请号:US467888

    申请日:1995-06-06

    IPC分类号: C07C405/00 A61K31/557

    摘要: The invention relates to 9-halogen-(Z) prostane derivatives of formula I ##STR1## in which ##STR2## Z represents the radicals Hal represents a chlorine or fluorine atom,R.sub.1 represents ##STR3## A represents a --CH.sub.2 --CH.sub.2 --, a trans--CH=CH or --C.ident.C, W represents a free or a functionally modified ##STR4## group, D and E together represent a direct bond orD represents a straight-chain alkylene group with 1-10 C atoms, a branched-chain alkylene group with 2-10 C atoms or an annular alkylene group with 3-10 C atoms, which optionally can be substituted by fluorine atoms, andE represents an oxygen or sulfur atom, a direct bond, a C.ident.C bond or a --CR.sub.6 =CR.sub.7 group, and R.sub.6 and R.sub.7 are different and mean a hydrogen atom, a chlorine atom or a C.sub.1 -C.sub.4 alkyl group,R.sub.4 represents a free or functionally modified hydroxy,R.sub.5 means a hydrogen atom, an alkyl, a halogen-substituted alkyl, a cycloalkyl or an optionally substituted aryl or a heterocyclic group.

    摘要翻译: 本发明涉及式I的9-卤代 - (Z)前列腺衍生物,其中,Z表示基团,Hal表示氯或氟原子,R1表示A表示 -CH 2 -CH 2 - ,反式-CH = CH或-C = C,W表示游离或官能改性的基团,D和E一起表示直接键或D表示直链亚烷基,其中1 -10个C原子,具有2-10个碳原子的支链亚烷基或具有3-10个C原子的环状亚烷基,其任选可以被氟原子取代,E表示氧或硫原子,直接键 ,C = C键或-CR6 = CR7基,R6和R7不同,表示氢原子,氯原子或C1-C4烷基,R4表示游离或官能改性的羟基,R5表示氢 原子,烷基,卤素取代的烷基,环烷基或任选取代的芳基或杂环基。

    Pharmaceutically active 9-chloroprostaglandins
    7.
    发明授权
    Pharmaceutically active 9-chloroprostaglandins 失效
    药用活性9-氯前列腺素

    公开(公告)号:US5204371A

    公开(公告)日:1993-04-20

    申请号:US792574

    申请日:1991-11-15

    IPC分类号: C07C405/00

    CPC分类号: C07C405/0041 C07C405/00

    摘要: Compounds of the formula ##STR1## wherein the 9-chlorine atom can be in the .alpha.-or .beta.-position,A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--,B is --CH.sub.2 --CH.sub.2,--, trans--CH.dbd.CH--, or --CH.tbd.C--, W is hydroxymethylene orD and E together represent a direct bond orD is a straight-chain or branched alkylene group of 1-10 carbon atoms, optionally substituted by fluorine, andE is oxygen or sulfur or a direct bond, andR.sub.4 is hydroxy or hydroxy etherified or esterified as defined for W above;R.sub.5 is a C.sub.1-10 hydrocarbon aliphatic group; a C.sub.1-10 hydrocarbon aliphatic group substituted by aryl, a substituted aryl as defined for R.sub.2 above, or halogen; or cycloalkyl, substituted cycloalkyl, aryl, substituted aryl or aromatic heterocyclic, all as defined for R.sub.2 above;or a physiologically acceptable salt thereof with a base when R.sub.1 is OH,have valuable pharmacologoical properties.

    摘要翻译: 其中9-氯原子可以是α-或β-位的式为“IMAGE”的化合物,A为-CH 2 -CH 2 - 或顺式-CH = CH-,B为-CH 2 -CH 2, - , CH = CH-或-CH 3 B - ,W是羟基亚甲基或D和E一起代表直接键,或D是1-10个碳原子的直链或支链亚烷基,任选被氟取代,E是 氧或硫或直接键,并且R4是如上定义的羟基或羟基醚化或酯化; R5是C1-10烃脂族基团; 被芳基取代的C1-10烃脂族基,对上述R2定义的取代芳基或卤素; 或环烷基,取代的环烷基,芳基,取代的芳基或芳族杂环,全部如上述R2所定义; 或其生理上可接受的盐,当R1为OH时,具有有价值的药理学性质。

    Pharmaceutically active 9-chloroprostaglandins
    8.
    发明授权
    Pharmaceutically active 9-chloroprostaglandins 失效
    药用活性9-氯前列腺素

    公开(公告)号:US4444788A

    公开(公告)日:1984-04-24

    申请号:US387140

    申请日:1982-06-10

    CPC分类号: C07C405/00 C07C405/0041

    摘要: Compounds of the formula ##STR1## wherein the 9-chlorine atom can be in the .alpha.- or .beta.-position,R.sub.1 is OR.sub.2, or NHR.sub.3 wherein R.sub.3 is H or the acyl group ofa C.sub.1-15 hydrocarbon carboxylic or sulfonic acid;A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--,B is --CH.sub.2 --CH.sub.2 --,trans--CH.dbd.CH--, or --C.tbd.C--, ##STR2## wherein the OH-group in each case can be in the .alpha.- or .beta.-position, and can be etherified or esterified by tetrahydropyranyl, tetrahydrofuranyl, .alpha.-ethoxyethyl, trimethylsilyl dimethyl, tert-butylsilyl, tribenzylsilyl, acetyl, propionyl, butyryl or benzoyl;D and E together represent a direct bond orD is a straight-chain or branched alkylene group of 1-10 carbon atoms, optionally substituted by fluorine, andE is oxygen or sulfur or a direct bond, andR.sub.4 is hydroxy or hydroxy etherified or esterified as defined for W above;R.sub.5 is a C.sub.1-10 hydrocarbon aliphatic group; a C.sub.1-10 hydrocarbon, aliphatic group substituted by aryl, a substituted aryl as defined for R.sub.2 above, or halogen; or cycloalkyl, substituted cycloalkyl, aryl, substituted aryl or aromatic heterocyclic, all as defined for R.sub.2 above;or a physiologically acceptable salt thereof with a base when R.sub.1 is OH,have valuable pharmacological properties.

    摘要翻译: 其中9-氯原子可以是α-或β-位,R1是OR2或NHR3,其中R3是H或C1-15烃羧酸或磺酸的酰基; A是-CH 2 -CH 2 - 或顺式-CH = CH-,B是-CH 2 -CH 2 - ,反式-CH = CH-或-C 3位C,,其中每种情况下的OH-基团可以是 四氢呋喃基,α-乙氧基乙基,三甲基甲硅烷基二甲基,叔丁基甲硅烷基,三苄基甲硅烷基,乙酰基,丙酰基,丁酰基或苯甲酰基可以醚化或酯化。 D和E一起代表直接键或D是1-10个碳原子的直链或支链亚烷基,任选被氟取代,E是氧或硫或直接键,并且R 4是羟基或羟基醚化或 酯化如上述W所定义; R5是C1-10烃脂族基团; C1-10烃基,被芳基取代的脂族基团,对上述R2定义的取代芳基或卤素; 或环烷基,取代的环烷基,芳基,取代的芳基或芳族杂环,全部如上述R2所定义; 或其生理上可接受的盐,当R1为OH时,具有有价值的药理学性质。

    .DELTA..sup.8,9 -Prostaglandin derivatives, their preparation and use as
medicinal agents
    9.
    发明授权
    .DELTA..sup.8,9 -Prostaglandin derivatives, their preparation and use as medicinal agents 失效
    DELTA 8,9-前列腺素衍生物,其制备和用作药物

    公开(公告)号:US4560786A

    公开(公告)日:1985-12-24

    申请号:US391734

    申请日:1982-06-24

    摘要: .DELTA..sup.8,9 -Prostane derivatives of Formula I ##STR1## wherein R.sub.1 is CH.sub.2 OH or ##STR2## wherein R.sub.2 is hydrogen, alkyl, cycloalkyl, aryl, or a heterocyclic residue; or R.sub.1 is ##STR3## wherein R.sub.3 is an acid residue or R.sub.2 ; A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH;B is --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH-- or --C.tbd.C--W is a free or functionally modified hydroxymethylene group or free or functionally modified ##STR4## wherein the OH--group can be in the .alpha.-- or .beta.-- position; D and E jointly are a direct bond orD is straight chain or branched alkylene or alkenylene of 1-10 carbon atoms which can optionally be substituted by fluorine atoms, and E is oxygen, sulfur, a direct bond, --C.tbd.C-- or --CR.sub.6 .dbd.CR.sub.7 --, wherein R.sub.6 and R.sub.7 differ from each other and each is hydrogen, chlorine or alkyl;R.sub.4 is free or functionally modified hydroxy andR.sub.5 is an optionally substituted aliphatic group, cycloalkyl, optionally substituted aryl, or a heterocyclic group, and when R.sub.2 is hydrogen, physiologically compatible salts thereof with bases,have valuable pharmacological properties, e.g. luteolytic and abortifacient activities.

    摘要翻译: DELTA 8,9-式I的前驱体衍生物其中R 1是CH 2 OH或其中R 2是氢,烷基,环烷基,芳基或杂环残基; 或R 1为,其中R 3为酸残基或R 2; A是-CH 2 -CH 2 - 或顺式-CH = CH; B是-CH 2 -CH 2 - ,反式-CH = CH-或-C 3BOND C-W是游离或官能改性的羟基亚甲基或游离或官能改性的“IMAGE”,其中OH-基团可以是α或β - 位置 D和E共同是直接键合,或D是可以任选被氟原子取代的1-10个碳原子的直链或支链亚烷基或亚烯基,并且E是氧,硫,直接键,-C 3 D或 -CR 6 = CR 7 - ,其中R 6和R 7彼此不同,各自为氢,氯或烷基; R4是游离的或官能改性的羟基,R 5是任选取代的脂族基,环烷基,任选取代的芳基或杂环基,当R 2是氢时,其与碱的生理上相容的盐具有有价值的药理学性质。 luteolytic和流产活动。

    9-Fluoroprostaglandin derivatives, and use as medicinal agents
    10.
    发明授权
    9-Fluoroprostaglandin derivatives, and use as medicinal agents 失效
    9-氟前列腺素衍生物,用作药物

    公开(公告)号:US4454339A

    公开(公告)日:1984-06-12

    申请号:US395448

    申请日:1982-07-06

    摘要: 9-Fluoroprostane derivatives of Formula I ##STR1## wherein R.sub.1 is CH.sub.2 OH or ##STR2## wherein R.sub.2 is hydrogen, alkyl, cycloalkyl, aryl, or a heterocyclic residue; or R.sub.1 is the residue ##STR3## wherein R.sub.3 is an acid residue or R.sub.2 and A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--,B is --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH-- or --C.tbd.C,W is a free or functionally modified hydroxymethylene group wherein the OH-group can be in the .alpha.- or .beta.-position,D and E jointly are a direct bond orD is straight-chain or branched alkylene or alkenylene of 1-10 carbon atoms which can optionally be substituted by fluorine atoms, and E is oxygen or sulfur, a direct bond, --C.tbd.C-- or --CR.sub.6 .dbd.CR.sub.7 -- wherein R.sub.6 and R.sub.7 differ from each other and each is hydrogen, chlorine, or alkyl,R.sub.4 is a free or functionally modified hydroxy group, andR.sub.5 is hydrogen, an optionally substituted aliphatic group, e.g., alkyl or halosubstituted alkyl, cycloalkyl, optionally substituted aryl or a heterocyclic group, and, when R.sub.2 is H, physiologically compatible salts thereof with bases,have valuable pharmacological properties, e.g., as luteolytics or abortifacients.

    摘要翻译: 其中R 1是CH 2 OH或其中R 2是氢,烷基,环烷基,芳基或杂环残基的式I的1-氟代衍生物(Ⅰ) 或R1是残基,其中R3是酸残基或R2和A是-CH2-CH2-或顺式-CH = CH-,B是-CH2-CH2-,反式-CH = CH-或-C3BOND C,W是游离的或官能改性的羟基亚甲基,其中OH基可以是α-或β-位,D和E共同是直接键,或D是1-10的直链或支链亚烷基或亚烯基 可以任选被氟原子取代的碳原子,E是氧或硫,直接键,-C 3 D或-CR 6 = CR 7 - ,其中R 6和R 7彼此不同,各自是氢,氯或烷基 R4是游离的或官能改性的羟基,R5是氢,任意取代的脂族基团,例如烷基或卤代取代的烷基,环烷基,任选取代的芳基或杂环基,当R 2是H时,其生理上相容的盐 具有碱性,具有有价值的药理学性质,例如作为纤溶素或流产。